Wolverine Peptide Stack: BPC-157 and TB-500 Protocol Guide

The Wolverine stack is not a product. It is a nickname, borrowed from the comic book character with accelerated healing, for running BPC-157 and TB-500 at the same time. No vendor owns the term, there is no proprietary blend behind it, and the two compounds in it have been sold separately for years.

That matters, because the name does a lot of marketing work that the evidence does not fully support. The stack is genuinely popular among people rehabbing stubborn soft tissue injuries, and the rationale for combining the two is sound. But almost all of the supporting data is animal research, and the results people report vary widely. This guide covers what the stack is, why the two compounds are paired, the standard protocol, and what you should realistically expect.

What the Wolverine Stack Actually Is

Two compounds, run concurrently:

• BPC-157, a 15 amino acid fragment derived from a protein found in human gastric juice. It acts most strongly near the site of administration and is dosed daily in microgram quantities.
• TB-500, a 17 amino acid synthetic fragment of Thymosin Beta-4. It distributes systemically, requires a loading phase, and is dosed twice weekly in milligram quantities.

Some vendors sell a premixed vial marketed under the Wolverine name. There is nothing wrong with a blend in principle, but it removes your ability to adjust one compound independently, which is the main reason experienced users run them separately. If a blend does not disclose the exact milligram content of each component on the label and the Certificate of Analysis, treat that as a reason to buy the two compounds individually.

Why the Two Compounds Are Stacked

The pairing is not arbitrary. BPC-157 and TB-500 act through different, largely non-overlapping mechanisms, which is the strongest argument for running them together rather than doubling the dose of either one.

BPC-157: the local repair signal

BPC-157 upregulates growth hormone receptor expression in fibroblasts and increases nitric oxide production. In animal models it has accelerated healing in tendon, ligament, muscle and gut tissue, and its effect is strongest close to where it was injected. This is why users targeting a specific injury typically inject as near to the site as is practical, a technique covered in the injection guide. The full mechanism and dosing detail sits in the BPC-157 complete guide.

TB-500: the systemic one

TB-500 binds actin and promotes cell migration and angiogenesis throughout the body rather than at one location. That systemic reach is the reason it needs a loading phase: you are building a tissue concentration, not delivering a local dose. It suits chronic, widespread or multi site problems better than a single acute injury. The TB-500 guide covers the loading maths in more depth.

Put simply, BPC-157 works on the spot you point it at, and TB-500 works on everything. If you are only dealing with one fresh, well localised injury, BPC-157 alone is often enough and considerably cheaper. The direct comparison between the two goes further into when a single compound is the better call.

The Standard Wolverine Stack Protocol

The protocol below is the one most commonly reported in the peptide community. It is not a clinical dosing schedule, because none exists for either compound in humans.

Both compounds ship lyophilised and need reconstituting with bacteriostatic water before use. Getting the concentration right is where most beginners go wrong, and an error here means every subsequent dose is wrong too. Work through the reconstitution guide before you draw anything, and store reconstituted vials according to the storage and stability guide, since neither compound tolerates room temperature for long once mixed.

What the Evidence Actually Supports

This is the part most Wolverine stack content skips. Both compounds have a genuinely interesting preclinical literature and almost no human trial data.

BPC-157 has been studied in rodents across tendon, muscle, ligament, nerve and gastrointestinal injury models, with fairly consistent positive results. Thymosin Beta-4, the parent protein of TB-500, reached human clinical trials for dry eye and for pressure ulcers, and results were mixed. TB-500 itself, the synthetic fragment sold to researchers, has not been through equivalent human testing.

What that means practically: the mechanistic rationale is real, the animal data is encouraging, and the human evidence base is thin enough that anyone promising a specific outcome is guessing. Neither compound is FDA approved for any indication. Both are sold for research purposes only.

Realistic Timeline

Users who report benefit tend to describe a fairly consistent sequence:

• Weeks 1 to 2. Little to nothing. Some report reduced pain at the injury site toward the end of week two, more often with BPC-157 than TB-500.
• Weeks 2 to 4. BPC-157 effects become more apparent. This is where localised injuries most often show change. TB-500 is still loading.
• Weeks 4 to 6. TB-500 reaches tissue saturation. Users describe a broader effect here, including improvements in areas that were not the primary target.
• Weeks 6 to 8. The clearest window for the stack overall. If nothing has changed by the end of week eight, a longer cycle is unlikely to help.

A caveat worth stating plainly: injuries also heal on their own, and eight weeks is long enough for meaningful natural recovery. Self reported peptide results carry a large placebo and natural healing component that no amount of anecdote can separate out.

Side Effects and Contraindications

Reported side effects for both compounds are generally mild. BPC-157 users report injection site irritation and occasional light headedness. TB-500 users most commonly report fatigue or lethargy in the first few days, likely tied to systemic cellular activity, plus occasional headache. Most of it clears within the first week. The BPC-157 side effects breakdown and the broader peptide side effects overview cover the reported picture in detail.

The contraindications matter more than the side effects. Anyone with active or recently treated cancer should avoid both compounds entirely. Angiogenesis and cell migration are the mechanisms that make these peptides useful for healing, and they are theoretically capable of supporting tumour growth. The risk is unproven, and it is still not worth taking. Anyone pregnant or breastfeeding should avoid both, as should anyone on anticoagulant therapy without clinician oversight.

Tested athletes should note that TB-500 is on the WADA Prohibited List. BPC-157 is on the monitoring program and is not prohibited as of 2026, but the stack as a whole is not compatible with drug tested competition.

Cost of a Cycle

At 2026 research vendor pricing, a six week Wolverine cycle typically lands between 200 and 400 US dollars. BPC-157 is the cheap component, usually 30 to 60 dollars for a 5mg vial, and a 250mcg daily protocol makes a vial last around three weeks. TB-500 carries most of the cost because the loading phase burns through milligram quantities, and a 5mg vial covers roughly one to two weeks of loading.

Buying multi vial kits usually drops the per milligram cost meaningfully. So does buying the two compounds separately rather than as a premixed Wolverine blend, which tends to carry a naming premium. Cycle planning across multiple compounds is covered in the peptide cycles guide.

Sourcing BPC-157 and TB-500

Product quality is the single largest practical variable in this stack. Both compounds are widely counterfeited and underdosed because demand is high and buyers cannot verify peptide content without lab testing. Insist on a third party Certificate of Analysis showing purity at 98% or higher, with a lot number that matches the vial in your hand. A COA that is not lot matched is a marketing document, not a test result. The peptide testing guide covers independent verification if you want to check a vial yourself.

Vendors the Bureau has scored well for both compounds:

• Apollo Peptide Sciences stocks both BPC-157 and TB-500 with consistent lot matched COAs and competitive multi vial pricing.
• Pantheon Peptides scores highest on the Bureau scorecard for recovery compounds specifically, and carries both halves of the stack.
• Amino Club is usually the cheapest of the three on BPC-157, which matters if you are running the compound alone first.
• Ascension Peptides maintains strong batch testing documentation and is a reliable second source if your primary vendor is out of stock.

The full rankings, including the vendors that failed testing, are in the 2026 vendor scorecard.

Common Questions

Is the Wolverine stack better than BPC-157 alone?

For chronic or multi site problems that have not responded to BPC-157 by itself, most users say yes. For a single fresh injury, BPC-157 alone is often sufficient and roughly a third of the cost. The stack is an escalation, not a starting point.

Can I inject both in the same syringe?

Yes, provided both are reconstituted with bacteriostatic water. They do not interact negatively. Separate injections give you more dosing precision if you plan to adjust one compound independently, which is usually the case.

Does the stack help with joint pain specifically?

Reports are mixed and depend heavily on what is causing the pain. Tendon and ligament involvement responds better in anecdotal reports than degenerative joint changes. The joint pain protocol and the tendon repair evidence review break down what the research supports for each.

What happens if I run it longer than eight weeks?

Nobody knows. Continuous long term use of either compound is not studied in humans, and there is no safety data past a few months. The standard advice to cycle off after eight weeks is a precaution rather than an evidence based limit.

Are oral versions worth it?

Oral BPC-157 has a plausible case for gut specific issues because it acts in the GI tract directly, covered in the oral BPC-157 analysis. For systemic or musculoskeletal goals, oral absorption is poor and injection is the standard route. There is no meaningful oral TB-500.